Rua Diagnostics Inc. — SEC Form D Filing

Rua Diagnostics Inc. filed an SEC Form D on May 27, 2026, reporting $3.65M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
May 27, 2026
Amount reported
$3.65M
Round stage
Seed
Industry
Health Technology
Website
https://www.ruadiagnostics.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: NEW YORK

Problem

Lung cancer, colorectal cancer, and COVID-19 are serious health concerns due to their often late detection and significant global impact.

Solution

Rua Diagnostics is developing BreathScan technology, utilizing breath analysis with gas chromatography to diagnose diseases such as lung cancer, colon cancer, and COVID-19 through a simple, non-invasive breath test.

Why now

The need for early detection methods in diagnostics is crucial due to the rising incidence of diseases like cancer and the ongoing impact of COVID-19.

Verdict

Investors said yes at this moment primarily due to the urgent need for non-invasive diagnostic tools, betting on the uniqueness of breath analysis to capture a growing healthcare demand. This cleared because early detection with fewer procedural risks is highly valued, not because existing diagnostic methods aren't already established and reliable. The limited upside lies in potential competition from scalable traditional technologies and other innovative diagnostics pushing into the same space.

Source: SEC EDGAR Form D filing